Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Vascular Biogenics Ltd. (VBLT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.4900+0.0900 (+6.43%)
At close: 04:00PM EDT
1.5600 +0.07 (+4.70%)
After hours: 04:33PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.4000
Open1.4100
Bid1.0000 x 800
Ask1.6000 x 2200
Day's Range1.4006 - 1.4900
52 Week Range1.1000 - 2.5900
Volume41,846
Avg. Volume165,891
Market Cap103.255M
Beta (5Y Monthly)1.15
PE Ratio (TTM)N/A
EPS (TTM)-0.4710
Earnings DateMar 23, 2022 - Mar 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.30
  • GlobeNewswire

    VBL Therapeutics to Participate in the Jefferies Healthcare Conference

    TEL AVIV, Israel and NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, will present a corporate overview and participate in investor meetings at the upcoming Jefferies Healthcare Conference being held in New York o

  • Zacks

    Vascular Biogenics (VBLT) Reports Q1 Loss, Misses Revenue Estimates

    Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -8.33% and 42.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    VBL Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

    OVAL Phase 3 top-line data expected in 2H 2022; with positive results, VBL anticipates submitting a BLA to the FDA in 1H 2023 Conference Call and Webcast at 8:30 a.m. ET Today TEL AVIV, Israel and NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced financial results for the first quar

Advertisement
Advertisement